Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
21 hedge funds and large institutions have $1.29M invested in Celgene Corporation Contingent Value Rights in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
4% more capital invested
Capital invested by funds: $1.25M → $1.29M (+$46.7K)
5% less funds holding
Funds holding: 22 → 21 (-1)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Davenport & Co
Richmond,
Virginia
|
+$12.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.85K |
| 3 |
Morgan Stanley
New York
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UAS
United Asset Strategies
Garden City,
New York
|
-$121K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$12K |
| 3 |
FA
FCG Advisors
Chatham,
New Jersey
|
-$6.34K |
| 4 |
First Manhattan
New York
|
-$3.44K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$1.12K |
CELGZ Hedge Fund Activity: Q2 2017 in Review
21 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q2 2017, worth a combined $1.29M — up 3.7% from $1.25M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CELGZ and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Davenport & Co, adding an estimated $12.3K. The largest seller was United Asset Strategies, exiting entirely with an estimated $121K sold.
- 21 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q2 2017, down from 22 in Q1 2017.
- Funds reported $1.29M of Celgene Corporation Contingent Value Rights stock for Q2 2017, up 3.7% quarter-over-quarter.
- 0 funds opened new Celgene Corporation Contingent Value Rights positions in Q2 2017 and 1 closed out, a net change of -1 holder.
- The largest Celgene Corporation Contingent Value Rights buyer in Q2 2017 was Davenport & Co, an estimated $12.3K added.
- The largest Celgene Corporation Contingent Value Rights seller in Q2 2017 was United Asset Strategies, an estimated $121K sold.
Based on aggregated 13F filings for Q2 2017.